<DOC>
	<DOCNO>NCT01592500</DOCNO>
	<brief_summary>This phase II , open label , active-controlled , randomized safety dose find study different MOD-4023 dose level compare daily r-hGH therapy pre-pubertal growth hormone deficient child .</brief_summary>
	<brief_title>Safety Efficacy Phase 2 Study Long-acting hGH ( MOD-4023 ) Growth Hormone Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Prepubertal child age ≥ 3 yr old 10 year girls 11 year boys either isolated GHD , GH insufficiency part multiple pituitary hormone deficiency . 2 . Confirmed diagnosis GHD two different GH provocation test define peak plasma GH level ≤7 ng/ml , determine central laboratory use validate assay . 3 . Bone age ( BA ) old chronological age great 9 year girls 10 year boys . 4 . Without prior exposure rhGH therapy . 5 . Normal birth size , birth weight length gestational age 6 . Impaired height height velocity define : 1 . Height ( HT ) least 2.0 standard deviation ( SD ) mean height chronological age ( CA ) gender accord standard Prader et . al , 1989 , ( HT SDS ≤ 2.0 ) . 2 . Annualized height velocity ( HV ) 25th percentile CA ( HV &lt; 0.7 SDS ) gender accord standard Prader et al ( 1989 ) . The interval two height measurement least 6 month inclusion . 7 . BMI must within ±2 SD mean BMI chronological age sex accord 2000 CDC standard . 8 . Baseline IGFI level least 1 SD mean IGFI level standardize age sex ( IGFI SDS ≤ 1.0 ) accord central laboratory reference value ; 9 . 12 . Written inform consent parent legal guardian patient assent patient ( patient read ) . 1 . Children past present intracranial tumor growth confirm MRI scan ( contrast ) . 2 . History radiation therapy chemotherapy . 3 . Malnourished child define : 1 . Serum albumin low limit normal ( LLN ) accord reference range central laboratory ; 2 . Serum iron lower limit normal ( LLN ) accord reference range central laboratory ; 3 . BMI &lt; 2 SD age sex ; 4 . Children psychosocial dwarfism . 5 . Children born small gestational age ( SGA birth weight and/or birth length &lt; 2 SD gestational age ) . 6 . Presence antihGH antibody screen . 7 . Any clinically significant abnormality likely affect growth ability evaluate growth , , limit , chronic disease like renal insufficiency , spinal cord irradiation , etc . 8 . Patients diabetes mellitus . 9 . Patients impaired fasting sugar ( base WHO ; fast blood sugar &gt; 110 mg/dl 6.1 mmol/l ) repeat blood analysis . 10 . Chromosomal abnormality medical `` syndrome '' ( Turner 's syndrome , Laron syndrome , Noonan syndrome , PraderWilli Syndrome , RussellSilver Syndrome , SHOX mutations/deletions skeletal dysplasia ) , exception septooptic dysplasia . 11 . Closed epiphysis . 12 . Concomitant administration treatment may effect growth anabolic steroid methylphenidate attention deficit hyperactivity disorder ( ADHD ) , exception hormone replacement therapy ( thyroxine , hydrocortisone , desmopressin ( DDAVP ) ) 13 . Children require glucocorticoid therapy ( e.g . asthma ) take dose great 400 µg/d inhale budesonide equivalent longer 1 month calendar year . 14 . Major medical condition and/or presence contraindication rhGH treatment . 15 . Known suspected HIVpositive patient , patient advance disease AIDS tuberculosis . 16 . Drug , substance , alcohol abuse . 17 . Known hypersensitivity component study medication . 18 . Other cause short stature coeliac disease , hypothyroidism rickets . 19 . The patient and/or parent/legal guardian likely noncompliant respect study conduct . 20 . Participation trial investigational agent within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>GHD</keyword>
	<keyword>r-hGH</keyword>
	<keyword>Long-acting</keyword>
</DOC>